Asset Management One Co. Ltd. Grows Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Asset Management One Co. Ltd. boosted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 4.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 190,876 shares of the medical research company's stock after purchasing an additional 7,595 shares during the quarter. Asset Management One Co. Ltd.'s holdings in Thermo Fisher Scientific were worth $101,722,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of TMO. Halpern Financial Inc. grew its stake in Thermo Fisher Scientific by 307.7% in the 3rd quarter. Halpern Financial Inc. now owns 53 shares of the medical research company's stock valued at $27,000 after acquiring an additional 40 shares during the last quarter. Coppell Advisory Solutions LLC purchased a new position in Thermo Fisher Scientific in the 2nd quarter valued at about $33,000. Live Oak Investment Partners purchased a new position in Thermo Fisher Scientific in the 4th quarter valued at about $36,000. Tyler Stone Wealth Management purchased a new position in Thermo Fisher Scientific in the 2nd quarter valued at about $37,000. Finally, Indiana Trust & Investment Management CO purchased a new position in Thermo Fisher Scientific in the 3rd quarter valued at about $38,000. Hedge funds and other institutional investors own 89.23% of the company's stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on TMO shares. Robert W. Baird reiterated an "outperform" rating and set a $670.00 price objective on shares of Thermo Fisher Scientific in a report on Thursday, December 14th. Wolfe Research started coverage on shares of Thermo Fisher Scientific in a report on Wednesday, December 13th. They set an "outperform" rating and a $575.00 price objective on the stock. Raymond James increased their price objective on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an "outperform" rating in a report on Thursday, February 1st. HSBC began coverage on shares of Thermo Fisher Scientific in a report on Monday, December 18th. They set a "buy" rating and a $610.00 price objective on the stock. Finally, TheStreet upgraded shares of Thermo Fisher Scientific from a "c+" rating to a "b-" rating in a report on Friday, December 22nd. Five analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of "Moderate Buy" and an average price target of $599.00.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total value of $5,979,800.00. Following the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at $74,039,491.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at $74,039,491.68. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Marc N. Casper sold 5,547 shares of Thermo Fisher Scientific stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $550.62, for a total value of $3,054,289.14. Following the transaction, the chief executive officer now directly owns 43,608 shares in the company, valued at $24,011,436.96. The disclosure for this sale can be found here. Over the last three months, insiders have sold 50,277 shares of company stock worth $28,513,384. 0.32% of the stock is owned by insiders.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock traded down $5.44 during mid-day trading on Thursday, reaching $570.56. The company's stock had a trading volume of 1,230,977 shares, compared to its average volume of 1,589,600. The firm has a market cap of $217.56 billion, a price-to-earnings ratio of 37.56, a PEG ratio of 2.40 and a beta of 0.80. The business has a 50 day moving average price of $568.11 and a 200-day moving average price of $522.46. The company has a current ratio of 1.75, a quick ratio of 1.39 and a debt-to-equity ratio of 0.67. Thermo Fisher Scientific Inc. has a twelve month low of $415.60 and a twelve month high of $603.82.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, topping analysts' consensus estimates of $5.64 by $0.03. The firm had revenue of $10.89 billion during the quarter, compared to the consensus estimate of $10.73 billion. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The firm's revenue was down 4.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $5.40 earnings per share. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 21.52 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, April 15th. Shareholders of record on Friday, March 15th will be paid a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.35. The ex-dividend date of this dividend is Thursday, March 14th. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.10%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.